Should I buy or sell Cingulate stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks .

What is Cingulate's stock price target for 2024?

3 brokerages have issued 12 month price objectives for Cingulate's stock. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts .

How have CING shares performed in 2024?

Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING shares have decreased by 84.3% and is now trading at $1.20. View the best growth stocks for 2024 here .

When is Cingulate's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024. View our CING earnings forecast .

When did Cingulate's stock split?

Shares of Cingulate reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Cingulate IPO?

(CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.

How do I buy shares of Cingulate?

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

$1.20

-0.05 (-4.00%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $1.12
▼
$1.24
50-Day Range: $1.09
▼
$9.82
52-Week Range: $1.03
▼
$38.60

Volume: 213,900 shs
Average Volume: 511,182 shs
Market Capitalization: $1.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Cingulate alerts:

Cingulate MarketRank™ Stock Analysis

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 566.7% Upside
$8.00 Price Target
Short Interest: Healthy
0.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($24.40) to ($9.00) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Cingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Cingulate has a forecasted upside of 566.7% from its current price of $1.20.
Amount of Analyst Coverage
Cingulate has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.94% of the float of Cingulate has been sold short.
Short Interest Ratio / Days to Cover
Cingulate has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cingulate has recently decreased by 70.10%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cingulate does not currently pay a dividend.
Dividend Growth
Cingulate does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CING.

1.7

News and Social Media Coverage

News Sentiment
Cingulate has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Cingulate this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Cingulate to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cingulate insiders have not sold or bought any company stock.
Percentage Held by Insiders
38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.75% of the stock of Cingulate is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cingulate are expected to grow in the coming year, from ($24.40) to ($9.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cingulate is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cingulate is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cingulate has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cingulate Stock (NASDAQ:CING)

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

CING Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CING Stock News Headlines

February 8, 2024 | bizjournals.com

Pharma company Cingulate raises $7.5M from public offering

February 6, 2024 | markets.businessinsider.com

Cingulate Announces Closing of $7.5 Million Public Offering

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 5, 2024 | msn.com

Bullied teens' brains show chemical change associated with psychosis

February 5, 2024 | msn.com

Bullying May Leave Teens at Greater Risk of Psychosis

February 5, 2024 | benzinga.com

Peering Into Cingulate's Recent Short Interest

February 3, 2024 | seekingalpha.com

CINGW Cingulate Inc. WT EXP 121026

February 2, 2024 | msn.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.35%

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

February 2, 2024 | bizjournals.com

Cingulate sets a $7.5M goal for its latest public stock offering

February 2, 2024 | marketwatch.com

Cingulate Shares Drop 43% After Public Offering Prices

February 2, 2024 | markets.businessinsider.com

Cingulate Prices Offering Of 3.75 Mln Shares At $2/Share, Stock Tanks

February 2, 2024 | finance.yahoo.com

Cingulate Announces Pricing of $7.5 Million Public Offering

January 29, 2024 | bizjournals.com

Cingulate promotes exec to CFO amid dwindling capital

January 29, 2024 | finanznachrichten.de

Cingulate Inc.: Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

January 29, 2024 | finance.yahoo.com

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

January 29, 2024 | finance.yahoo.com

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

January 22, 2024 | bizjournals.com

Cingulate prepares another stock offering to raise money amid funding crunch

January 18, 2024 | bizjournals.com

KC execs face costly realities of leading life sciences startups

January 15, 2024 | msn.com

Cingulate files to sell common stock and warrants

January 11, 2024 | msn.com

Research reveals COVID-19's lasting impact on brain function and structure

January 9, 2024 | msn.com

New research provides an intriguing glimpse into how ketamine alters brain connectivity in depressed individuals

January 5, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Cingulate: Here's What You Need To Know

January 2, 2024 | wsj.com

Cingulate Inc.

December 28, 2023 | bizjournals.com

Cingulate receives second delisting warning following nearly entire board's exit

December 28, 2023 | benzinga.com

Crude Oil Down 1%; US Wholesale Inventories Fall In November

December 28, 2023 | msn.com

Why Is Neurology Focused Cingulate Stock Trading Higher Today?

See More Headlines

Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 2/12/2024
Next Earnings (Estimated): 3/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CING
CUSIP: N/A
CIK: 1862150
Web: www.cingulate.com
Phone: 913-942-2300
Fax: N/A
Employees: 15
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $8.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +566.7%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($32.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,235.83%
Return on Assets: -285.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.51
Quick Ratio: 0.51

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.87 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 940,000
Free Float: 577,000
Market Cap: $1.13 million
Optionable: Not Optionable
Beta: -0.63

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Shane J. Schaffer Pharm.D. (Age 49)
PharmD, CEO, Principal Financial Officer & Chairman of the Board
Comp: $504.69k
Dr. Laurie A. Myers M.B.A. (Age 67)
Ph.D., Executive VP & COO
Comp: $425k
Dr. Raul R. Silva M.D. (Age 66)
Executive VP & Chief Science Officer
Thomas Dalton
Head of Investor & Public Relations
Dr. Matthew N. Brams M.D. (Age 60)
Executive VP & Chief Medical Officer
Jennifer L. Callahan
Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CING Stock Analysis - Frequently Asked Questions

Should I buy or sell Cingulate stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares.
View CING analyst ratings or view top-rated stocks.
What is Cingulate's stock price target for 2024?: 3 brokerages have issued 12 month price objectives for Cingulate's stock. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 566.7% from the stock's current price.
View analysts price targets for CING or view top-rated stocks among Wall Street analysts.
How have CING shares performed in 2024?: Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING shares have decreased by 84.3% and is now trading at $1.20.
View the best growth stocks for 2024 here.
When is Cingulate's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our CING earnings forecast.

When did Cingulate's stock split?: Shares of Cingulate reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
When did Cingulate IPO?: (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share.
How do I buy shares of Cingulate?: Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CING) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial